Marketing-authorisation holder · United States
Fresenius Kabi USA, LLC
109 medicines in 1 country, as authorisation holder and manufacturer.
Loading your page…
Loading your page…
Marketing-authorisation holder · United States
109 medicines in 1 country, as authorisation holder and manufacturer.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1–25 of 109
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ACETAMINOPHEN1gm/100ml (10mg/ml) | 500mg/50ml (10mg/ml) | 650mg/65ml (10mg/ml) · Solution | Paracetamol | United States | Marketed | 2015 |
| ASCORBIC ACID25,000mg/50ml (500mg/ml) · Solution | Ascorbic acid | United States | Marketed | 2025 |
| ASTRAMORPH PF0.5mg/ml | 1mg/ml · Injectable | Morphine | United States | Not marketed | 1986 |
| BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER180mg/20ml (9mg/ml) | 270mg/30ml (9mg/ml) | 90mg/10ml (9mg/ml) · Solution | Sodium chloride | United States | Marketed | 1982 |
| BENZTROPINE MESYLATE1mg/ml · Injectable | Benzatropine | United States | Marketed | 2009 |
| Bomyntra120mg/1.7ml (70mg/ml) · Injection | Denosumab | United States | Marketed | 2025 |
| BOMYNTRA120mg/1.7ml (70 mg/ml) · Injection | Denosumab | United States | Marketed | 2025 |
| CAFFEINE CITRATE30mg base/3ml (eq 10mg base/ml) · Solution | Caffeine | United States | Marketed | 2006 |
| CALCITONIN-SALMON200 iu/ml · Injectable | Calcitonin (salmon synthetic) | United States | Marketed | 2021 |
| CARBOPLATIN150mg/15ml (10mg/ml) | 1gm/100ml (10mg/ml) | 450mg/45ml (10mg/ml) | 50mg/5ml (10mg/ml) | 600mg/60ml (10mg/ml) · Injectable | Carboplatin | United States | Marketed | 2004 |
| CEFOTAXIME10gm base/vial | 1gm base/vial | 20gm base/vial | 2gm base/vial | 500mg base/vial · Injectable | Cefotaxime | United States | Not marketed | 2000 |
| CEFTRIAXONE100gm base/vial | 10gm base/vial | 1gm base/vial | 2gm base/vial | 500mg base/vial · Injectable | Ceftriaxone | United States | Marketed | 2005 |
| CISATRACURIUM BESYLATE PRESERVATIVE FREE10mg base/ml | 2mg base/ml · Injectable | Cisatracurium | United States | Marketed | 2012 |
| CLONIDINE HYDROCHLORIDE1mg/10ml (0.1mg/ml) | 5mg/10ml (0.5mg/ml) · Injectable | Clonidine | United States | Marketed | 2009 |
| CONEXXENCE60mg/ml · Injection | Denosumab | United States | Marketed | 2025 |
| CYTARABINE100MG/ML | 100MG/VIAL | 100MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 1GM/VIAL | 1GM/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 20MG/ML | 2GM/VIAL | 2GM/VIAL **Federal Register determination that product was not discontinued or withd · Injectable | Cytarabine | United States | Marketed | 1969 |
| DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE10mg phosphate/ml · Injectable | Dexamethasone | United States | Marketed | 2003 |
| DEXTROSE 5% AND LACTATED RINGER'S20mg/100ml; 5gm/100ml; 30mg/100ml; 600mg/100ml; 310mg/100ml · Injectable | Calcium chloride, Dextrose, Potassium chloride, Sodium chloride, Sodium lactate | United States | Marketed | 2022 |
| DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075%5gm/100ml; 75mg/100ml · Injectable | Dextrose, Potassium chloride | United States | Marketed | 2020 |
| DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15%5gm/100ml; 150mg/100ml · Injectable | Dextrose, Potassium chloride | United States | Marketed | 2020 |
| DEXTROSE 5% AND SODIUM CHLORIDE 0.225%5gm/100ml; 225mg/100ml · Injectable | Dextrose, Sodium chloride | United States | Marketed | 2020 |
| DEXTROSE 5% AND SODIUM CHLORIDE 0.45%5gm/100ml; 450mg/100ml · Injectable | Dextrose, Sodium chloride | United States | Marketed | 2020 |
| DEXTROSE 5% AND SODIUM CHLORIDE 0.9%5gm/100ml; 900mg/100ml · Injectable | Dextrose, Sodium chloride | United States | Marketed | 2020 |
| DILAUDID0.2mg/ml | 0.5mg/0.5ml | 1mg/ml | 2mg/ml | 4mg/ml · Injectable | Hydromorphone | United States | Marketed | 1984 |
| DILAUDID-HP10mg/ml | 250mg/vial · Injectable | Hydromorphone | United States | Marketed | 1984 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 109 | 107 | 2 | CompaniesAll medicines |
Also in the registers of Singapore
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Contains information from HSA Listing of Registered Therapeutic Products accessed on 8 October 2026 from data.gov.sg, under Singapore Open Data Licence 1.0: https://data.gov.sg/open-data-licence
Licence: Singapore Open Data Licence
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.
Ranked by their number of medicines.